Simulations Plus, Inc. , a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn.
Total revenue of $18.3 million and diluted earnings per share of $0.20
Maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68
.
Simulations Plus, Inc. ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024..